Atopic Dermatitis-Vaccine Response Clinical Research Trial (40 Weeks)

Recruiting adults age 18 to 54 years with a diagnosis of atopic dermatitis (AD) that has been present for at least 6 months, to participate in this  clinical research trial. Must have a history of inadequate response to topical corticosteroids of medium-potency or high-potency, or for whom  topical treatments are otherwise medically inadvisable. Moderate to severe AD at initial screening and day 1 pre-randomization, is also required. Participants will receive investigational treatment (active study drug) or placebo, via subcutaneous injection. At Week 20, tetanus and  meningococcal vaccines will be administered to each participant. Study treatment and study-related assessments will be provided at no cost.  Reimbursement for study-related expenses may be provided. Study participation will last about 40 weeks and involve about 10 visits to the study centre.